MedTrace Logo

MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

NCT02269319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-11-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

Conditions

Interventions

DRUG

MRX-I

Oral MRX-I 800mg given twice a day for 10 days

DRUG

Linezolid

Oral linezolid 600mg given twice a day for 10 days

Sponsors & Collaborators

  • MicuRx

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-08-31
Completion
2015-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02269319 on ClinicalTrials.gov